AbbVie Inc. (NYSE:ABBV) is one of the top low volatility healthcare stocks to buy now. In a report released on July 22, Vamil ...

AbbVie Inc. (NYSE:ABBV) ranks among the best low volatility stocks to buy according to analysts. Ahead of the company’s ...

A look at the shareholders of AbbVie Inc. (NYSE:ABBV) can tell us which group is most powerful. We can see that institutions ...

We came across a bullish thesis on AbbVie Inc. on Dividend Talks’s Substack. In this article, we will summarize the bulls’ thesis on ABBV. AbbVie Inc.’s share was trading at $185.62 as of June 30th.

According to the update, the $823 million expense is related to acquired IPR&D, typically incurred through collaborations, ...

Shares of AbbVie Inc. ABBV advanced 1.22% to $187.11 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.06% to 6,309.62 and the ...

AbbVie for years delayed competition for its blockbuster drug Humira, at the expense of patients and taxpayers. The monopoly is about to end. By Rebecca Robbins ...

A Delaware federal jury said on Friday that Revance Therapeutics owes AbbVie's Allergan Inc $56 million after finding that ...

AbbVie Inc. raised its profit outlook for this year and next as demand for newer biologic drugs helped fill the gap left by falling Humira sales, but investors were disappointed as Botox sales ...

This was the stock's third consecutive day of losses.